CERE-120 with Best Medical Therapy (BMT) v BMT in Parkinson's Disease
Research type
Research Study
Full title
A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2-Neurturin) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease
IRAS ID
1867
Contact name
Patricia Limousin
Contact email
Sponsor organisation
Ceregene, Inc.
Eudract number
2007-006721-27
ISRCTN Number
N/A
Clinicaltrials.gov Identifier
N/A
Research summary
The purpose of this study is firstly to see if an experimental drug called CERE-120 is safe when given to people with Parkinson’s disease and secondly to see whether CERE-120 can improve symptoms of Parkinson’s disease . The CERE-120 drug is injected via surgery into small areas of the brain. CERE-120 is made by combining a virus called AAV (adeno-associated virus) that is modified with a gene that makes a protein called neurturin. Once injected in the brain, CERE-120 will get into the brain cells and produce neurturin. Neurturin produced in these cells can help these and other cells around the site of injection, including brain cells that produce dopamine, to become or remain healthy. The company that is developing CERE-120 is called Ceregene, Incorporated.
REC name
London - West London & GTAC Research Ethics Committee
REC reference
GTAC159
Date of REC Opinion
13 Jan 2009
REC opinion
Further Information Favourable Opinion